Aroa Biosurgery reports low infection rates in 411-patient Myriad soft tissue reconstruction study

PUBT · 1d ago
Aroa Biosurgery reports low infection rates in 411-patient Myriad soft tissue reconstruction study
  • Aroa Biosurgery announced peer-reviewed interim results from its ongoing MASTRR Registry evaluating Myriad in complex soft-tissue reconstruction.
  • Results were published in Advances in Therapy, marking the latest disclosure from the registry rather than a future conference presentation.
  • The analysis reported a favorable safety profile, with low infection rates in a high-risk, real-world inpatient population.
  • No adverse events were deemed definitely related to Myriad products, supporting the device’s clinical positioning versus competing bioscaffolds.
  • The company cited strong commercial momentum, including 54% sales growth in FY26, as the evidence base expands.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aroa Biosurgery Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609062046PR_NEWS_USPR_____CN41694) on September 07, 2026, and is solely responsible for the information contained therein.